Repeated Intravenous Lidocaine Infusions for Patients with Fibromyalgia: Higher Doses of Lidocaine Have a Stronger and Longer-Lasting Effect on Pain Reduction
Wilderman Medical Clinic reviewed and analyzed the clinical database of 74 patients with fibromyalgia whose pain was treated with lidocaine infusions. Study participants reported an average reduction of their pain intensity scores by 2.41–3.62 points immediately after the lidocaine infusion which corresponded to 30.51–46.71% of short-term pain relief.
This trend of pain relief was closely maintained at follow-up, with patients reporting average pain relief from 30.23% to 40.68% that lasted for 8.68 -17.54 days on average depending on the dose of lidocaine and the addition of magnesium. Our study results demonstrated that increased doses of intravenous lidocaine (up to 7.5mg/kg of adjusted body weight) are effective and safe in a significant number of patients with fibromyalgia. With higher doses of lidocaine pain relief was sustained in duration and lasted longer after the treatment.
The results of this study were published in the Journal of Pain Medicine in 20202. The full text of the article is available here.
Igor Wilderman, MD, CCFP, FCFP, DAAPM, Olga Pugacheva, PhD, Vsevolod (Sev) Perelman, MD, MSc, CCFP(EM), FCFP, CEUS, CHSE-A, Michael C T Wansbrough, MD, MSc, CCFP(EM), CEUS, DTM&H, DLSTMH CHSE, Yuri Voznyak, HBSc, Lukasz Zolnierczyk, HBSc, Repeated Intravenous Lidocaine Infusions for Patients with Fibromyalgia: Higher Doses of Lidocaine Have a Stronger and Longer-Lasting Effect on Pain Reduction,Pain Med. 2020;21(6):1230-1239., https://doi.org/10.1093/pm/pnz251
Meniscus-Targeted Injections for Chronic Knee Pain Due to Meniscal Tears or Degenerative Fraying: A Retrospective Study
Wilderman Medical Clinic demonstrated a substantial benefit from meniscus-targeted corticosteroid injections (20 and 40 mg triamcinolone) into the painful knee.
We analyzed the electronic medical records of 175 patients who had meniscal tears or degenerative fraying and were treated with meniscal-targeted injections. Ultrasound-guided meniscus-targeted corticosteroid injections produced 5.68 weeks of pain relief on average with a decrease in pain intensity score of 2.14 points at follow-up visits. The results of this study were published in the Journal of Ultrasound Medicine in 20191.
You can read here the full text of the article.
Wilderman I, Berkovich R, Meaney C, Kleiner O, Perelman V. Meniscus-Targeted Injections for Chronic Knee Pain Due to Meniscal Tears or Degenerative Fraying: A Retrospective Study. J Ultrasound Med. 2019;38(11):2853-2859. doi:10.1002/jum.14987
A Qualitative Study to Explore Patient Perspectives of Prophylactic Treatment with OnabotulinumtoxinA for Chronic Migraine
Introduction: OnabotulinumtoxinA (OBT-A) is one of the most studied prophylactic treatments for chronic migraine. Large clinical trials, and now real-world studies, continue to provide evidence to support the use of OBT-A as an effective treatment to manage chronic migraines. The objective of this study was to explore patient experience and perception of prophylactic treatment with OBT-A for chronic migraine.
Click here to read the full article.